Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain

Peer Review reports

Original Submission
12 Dec 2023	Submitted	Original manuscript
4 Feb 2024	Reviewed	Reviewer Report
15 Feb 2024	Reviewed	Reviewer Report
31 May 2024	Author responded	Author comments - Juan Luis López-Belmonte
Resubmission - Version 2
31 May 2024	Submitted	Manuscript version 2
13 Jun 2024	Author responded	Author comments - Juan Luis López-Belmonte
Resubmission - Version 3
13 Jun 2024	Submitted	Manuscript version 3
23 Jun 2024	Reviewed	Reviewer Report
27 Jun 2024	Reviewed	Reviewer Report
20 Jul 2024	Author responded	Author comments - Juan Luis López-Belmonte
Resubmission - Version 4
20 Jul 2024	Submitted	Manuscript version 4
Publishing
23 Jul 2024	Editorially accepted
6 Sep 2024	Article published	10.1186/s12879-024-09642-0

Back to article page